Anonymous User
Login / Registration

a hepatologie

Gastroenterology and Hepatology

Gastroent Hepatol 2016; 70(2): 150– 156. doi:10.14735/amgh2016csgh.info01.

Sartan associated enteropathy – case report and review of the literature

Jiří Cyrany1,2, Tomáš Vašátko1, Markéta Nová  3, Eva Hovorková3, Jan Machač4, Juraj Szanyi4, Marcela Kopáčová  5

+ Affiliation


Sartan associated enteropathy is a sprue-like diarrhoeal disease induced by sartans (especially olmesartan), characterised by small intestinal damage: villous atrophy with lymphocytic infiltration of lamina propria is usually present and can be combined with intraepithelial lymphocytosis and/or subepithelial collagen deposits. Course of the disease can be severe, however withdrawal of the medication leads to a complete restoration; clinical signs can be reproduced by the drug rechallenge. This side effect is observed relatively rarely when compared to the number of patients treated by olmesartan. Nevertheless it represents a frequent and important diagnostic alternative in the cohort of patients with non-coeliac sprue. The disease is presumably caused by an autoimmune mechanism in predisposed individuals. We present a case report of telmisartan associated enteropathy.


angiotensin II type 1 receptor blockers, coeliac disease, enteropathy, olmesartan, sprue

To read this article in full, please register for free on this website.

Benefits for subscribers

Benefits for logged users


1. U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA approves label changes to include intestinal
problems (sprue-like enteropathy) linked to blood pressure medicine olmesartan medoxomil. [online]. Available from: UCM359496.pdf.
2. Rubio-Tapia A, Herman ML, Ludvigsson JF et al. Severe spruelike enteropathy associated with olmesartan. Mayo Clin Proc 2012; 87(8): 732–738. doi: 10.1016/j.mayocp.2012.06.003.
3. Ianiro G, Bibbò S, Montalto M et al. Systematic review: Sprue-like enteropathy associated with olmesartan. Aliment Pharmacol Ther 2014; 40(1): 16–23. doi: 10.1111/apt.12780.
4. Talbot GH. Small bowel histopathologic findings suggestive of celiac disease in an
asymptomatic patient receiving olmesartan. Mayo Clin Proc 2012; 87(12): 1231–1232. doi: 10.1016/j.mayocp.2012.09.011.
5. DeGaetani M, Tennyson CA, Lebwohl B et al. Villous atrophy and negative celiac serology: a diagnostic and therapeutic dilemma.Am J Gastroenterol 2013; 108(5): 647–653.
6. Dreifuss SE, Tomizawa Y, Farber NJ et al. Spruelike enteropathy associated with olmesartan: an unusual case of severe
diarrhea. Case Rep Gastrointest Med 2013; 2013: 618071. doi: 10.1155/2013/618071.
7. Nielsen JA, Steephen A, Lewin M. Angiotensin-II inhibitor (olmesartan)-induced collagenous sprue with resolution
following discontinuation of drug. World J Gastroenterol 2013; 19(40): 6928–6930. doi: 10.3748/wjg.v19.i40.6928.
8. Nunge D, Eoche M, Fumery M et al. Severe enteropathy with villous atrophy olmesartan medoxomil-associated. Therapie 2013; 68(6): 419–421. doi: 10.2515/therapie/2013057.
9. Stanich PP, Yearsley M, Meyer MM. Olmesartan-associated sprue-like enteropathy.J Clin Gastroenterol 2013; 47(10): 894–895. doi: 10.1097/MCG.0b013e31829a27e6.
10. Tran TH, Li H. Olmesartan and drug-induced enteropathy. P T 2014; 39(1): 47–50.
11. Theophile H, David XR, Miremont-Salame G et al. Five cases of sprue-like enteropathy in patients treated by  olmesartan. Dig Liver Dis 2014; 46(5): 465–459. doi: 10.1016/j.dld.2013.12.014.
12. Gaur V, Albeldawi M, Weber L. Chronic diarrhea and weight loss. Gastroenterology 2014; 146(2): 347,591. doi: 10.1053/j. gastro.2013.10.002.
13. de Fonseka A, Tuskey A, Moskaluk C. A case of olmesartan induced enteropathy. Inflamm Bowel Dis 2012; 18: S17.
14. Marthey L, Cadiot G, Seksik P et al. Olmesartan-associated enteropathy: results of a national survey. Aliment Pharmacol Ther 2014; 40(9): 1103–1109. doi: 10.1111/apt.12937.
15. Bhat N, Anupama NK, Yelsangikar A et al. Olmesartan-related sprue-like enteropathy. Indian J Gastroenterol 2014; 33(6): 564–567. doi: 10.1007/s12664-014-0506-7.
16. Fiorucci G, Puxeddu E, Colella R et al. Severe spruelike enteropathy due to olmesartan. Rev Esp Enferm Dig 2014; 106(2): 142–144.
17. Gallivan C, Brown I. Olmesartan induced enterocolitis. Pathology 2014; 46(4): 360–361. doi: 10.1097/PAT.0000000000000104.
18. Heerasing N, Hair C, Wallace S. Olmesartan-induced enteropathy. Intern Med J 2015;45(1): 117–118. doi: 10.1111/imj.12635.
19. Halevy D, Teeuwen U, Kohlhof P. A new spruelike disease as a cause of severe diarrhea. Dtsch Med Wochenschr 2014;
139(45): 2290–2293. doi: 10.1055/s-0034-1387342.
20. Ould Sidi Mohamed M, Colardelle P.Enteropathy due to olmesartan. Ann Cardiol Angeiol (Paris) 2015. doi: 10.1016/j.
21. van Beurden YH, Nijeboer P, Janssen J et al. Diarrhoea and malabsorption due to olmesartan use. Ned Tijdschr Geneeskd 2014; 158.
22. Cyrany J, Vasatko T, Machac J et al. Letter: telmisartan-associated enteropathy – is there any class effect? Aliment Pharmacol Ther 2014; 40(5): 569–570. doi:10.1111/apt.12850.
23. Cammarota G, Ianiro G, Bibbo S et al.Letter: telmisartan associated enteropathy – is there any class effect? Authors’
reply. Aliment Pharmacol Ther 2014; 40(5):570. doi: 10.1111/apt.12870.
24. Herman ML, Rubio-Tapia A, Wu TT et al. A case of severe sprue-like enteropathy associated with valsartan. ACG Case Rep J 2015; 2(2): 92–94. doi: 10.14309/crj.2015.15.
25. Scialom S, Malamut G, Meresse B et al. Gastrointestinal disorder associated with olmesartan mimics autoimmune enteropathy.PLoS One 2015; 10:(6). doi: 10.1371/ journal.pone.0125024.
26. de Araújo AA, Borba PB, de Souza FH et al. In a methotrexate-induced model of intestinal mucositis, olmesartan reduced inflammation and induced enteropathy characterized by severe diarrhea, weight loss, and reduced sucrose activity. Biol Pharm Bull 2015; 38(5): 746–752. doi: 10.1248/bpb.b14-00847.
27. Khan AS, Peter S, Wilcox CM. Olmesartan-induced enteropathy resembling celiac disease. Endoscopy 2014; 46 (Suppl 1):97– 98. doi: 10.1055/s-0033-1359132.
28. Fukushima M, Kitamoto H, Inokuma T et al. Severe spruelike enteropathy associated with olmesartan observed by double-balloon enteroscopy. Gastrointest Endosc 2016; 83(1): 269–270. doi: 10.1016/j.gie.2015.06.004.
29. Lagana SM, Braunstein ED, Arguelles-Grande C et al. Sprue-like histology in patients with abdominal pain taking olmesartan compared with other angiotensin receptor blockers. J Clin Pathol 2015; 68(1):29–32. doi: 10.1136/jclinpath-2014-202 615.
30. Rubio-Tapia A. Editorial: sprue-like enteropathy associated with Olmesartan broadening the differential diagnosis of
enteropathy. Aliment Pharmacol Ther 2014; 40(11–12): 1362–1363. doi: 10.1111/ apt.13000.
31. Marietta EV, Cartee A, Rishi A et al.Drug-induced enteropathy. Dig Dis 2015; 33(2): 215–220. doi: 10.1159/000370205.
32. Hartranft ME, Regal RE. „Triple Phase“ Budesonide Capsules for the Treatment of Olmesartan-Induced Enteropathy. Ann Pharmacother 2014; 48(9): 1234–1237.
33. Abdelghany M, Gonzalez L 3rd, Slater J et al. Olmesartan associated sprue-like enteropathy and colon perforation. Case Rep Gastrointest Med 2014; 2014: 494098. doi: 10.1155/2014/494098.
34. Naranjo CA, Busto U, Sellers EM et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30(2): 239–245.
35. Menne J, Haller H. Olmesartan and intestinal adverse effects in the ROADMAP study. Mayo Clin Proc 2012; 87(12): 1230–1231. doi: 10.1016/j.mayocp.2012.10.005.
36. Sanford ML, Nagel AK. A review of current evidence of Olmesartan medoxomil mimicking symptoms of celiac dis-
ease. J Pharm Pract 2014. doi: 10.1177/0897190014527320. 37. Padwal R, Lin M, Etminan M et al. Comparative
effectiveness of olmesartan and other angiotensin receptor blockers in diabetes mellitus: retrospective cohort study. Hypertension 2014; 63(5): 977–983. doi: 10.1161/HYPERTENSIONAHA.113.02855.
38. Greywoode R, Braunstein ED, Arguelles-Grande C et al. Olmesartan, other antihypertensives,and chronic diarrhea among patients undergoing endoscopic procedures: a case-control study. Mayo Clin Proc 2014; 89(9): 1239–1243. doi: 10.1016/j.mayocp.2014.05.012.
39. Basson M, Mezzarobba M, Weill A et al. Severe intestinal malabsorption associated with olmesartan: a French nationwide observational cohort study. Gut 2015. doi:10.1136/gutjnl-2015-309690.
40. Souhrn údajů o přípravku Sarten 10 mg. Sp.zn.sukls165021/2014. [online].Dostupné z:
41. Lebwohl B, Ludvigsson JF. Editorial: sprue-like enteropathy due to olmesartan and other angiotensin receptor blockers – the plot thickens. Aliment Pharmacol Ther 2014; 40(10): 1245–1246. doi: 10.1111/apt.12960.

Credited self-teaching test